Calendar

Sep
16
Wed
2020
IBIIS & AIMI Seminar – Judy Gichoya, MD @ Zoom - See Description for Zoom Link
Sep 16 @ 12:00 pm – 1:00 pm
IBIIS & AIMI Seminar - Judy Gichoya, MD @ Zoom - See Description for Zoom Link

Judy Gichoya, MD
Assistant Professor
Emory University School of Medicine

Measuring Learning Gains in Man-Machine Assemblage When Augmenting Radiology Work with Artificial Intelligence

Abstract
The work setting of the future presents an opportunity for human-technology partnerships, where a harmonious connection between human-technology produces unprecedented productivity gains. A conundrum at this human-technology frontier remains – will humans be augmented by technology or will technology be augmented by humans? We present our work on overcoming the conundrum of human and machine as separate entities and instead, treats them as an assemblage. As groundwork for the harmonious human-technology connection, this assemblage needs to learn to fit synergistically. This learning is called assemblage learning and it will be important for Artificial Intelligence (AI) applications in health care, where diagnostic and treatment decisions augmented by AI will have a direct and significant impact on patient care and outcomes. We describe how learning can be shared between assemblages, such that collective swarms of connected assemblages can be created. Our work is to demonstrate a symbiotic learning assemblage, such that envisioned productivity gains from AI can be achieved without loss of human jobs.

Specifically, we are evaluating the following research questions: Q1: How to develop assemblages, such that human-technology partnerships produce a “good fit” for visually based cognition-oriented tasks in radiology? Q2: What level of training should pre-exist in the individual human (radiologist) and independent machine learning model for human-technology partnerships to thrive? Q3: Which aspects and to what extent does an assemblage learning approach lead to reduced errors, improved accuracy, faster turn-around times, reduced fatigue, improved self-efficacy, and resilience?

Zoom: https://stanford.zoom.us/j/93580829522?pwd=ZVAxTCtEdkEzMWxjSEQwdlp0eThlUT09

Oct
6
Tue
2020
Early Detection of Cancer Conference @ Virtual Event
Oct 6 – Oct 8 all-day
Early Detection of Cancer Conference @ Virtual Event

Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford, present the Early Detection of Cancer Conference series. The annual Conference brings together experts in early detection from multiple disciplines to share ground breaking research and progress in the field.

The Conference is part of a long-term commitment to invest in early detection research, to understand the biology behind early stage cancers, find new detection and screening methods, and enhance uptake and accuracy of screening.

The 2020 conference will take place October 6-8 virtually.

 

Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford, have been closely monitoring developments relating to the coronavirus (COVID-19) outbreak and reviewing guidance from government bodies. After careful consideration, we have made the decision to convert the Early Detection of Cancer Conference 2020 to a virtual conference, instead of the scheduled in-person conference on October 6-8 in London, UK. 

 

For more information visit the website: http://earlydetectionresearch.com/

Oct
15
Thu
2020
Cancer Early Detection Seminar Series – Paul Boutros, Ph.D., M.B.A. @ Zoom - See Description for Zoom Link
Oct 15 @ 11:00 am – 12:00 pm
Cancer Early Detection Seminar Series - Paul Boutros, Ph.D., M.B.A. @ Zoom - See Description for Zoom Link

CEDSS: “The Origins and Detection of Lethal Prostate Cancer”

Paul Boutros, Ph.D., M.B.A.
Director, Cancer Data Sciences
UCLA

Please see zoom details below:
Meeting URL: https://stanford.zoom.us/s/93515779500
Dial: +1 650 724 9799 or +1 833 302 1536
Meeting ID: 935 1577 9500
Meeting Passcode: 767148

ABOUT
Boutros earned his B.Sc. degree from the University of Waterloo in Chemistry in 2004, and his Ph.D. degree from the University of Toronto, Canada, in Medical Biophysics in 2008. At Toronto, he also earned an executive M.B.A. from the Rothman School of Management. In 2008, Boutros started his independent research career at the Ontario Institute for Cancer Research first as a fellow (2008–2010) and then as principal investigator (2010–2018). He moved to California to join the UCLA faculty in 2018.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by the Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Nov
18
Wed
2020
IBIIS & AIMI Seminar: Deep Tomographic Imaging @ Zoom: https://stanford.zoom.us/j/96731559276?pwd=WG5zcEFwSGlPcDRsOUFkVlRhcEs2Zz09
Nov 18 @ 12:00 pm – 1:00 pm

Ge Wang, PhD
Clark & Crossan Endowed Chair Professor
Director of the Biomedical Imaging Center
Rensselaer Polytechnic Institute
Troy, New York

Abstract:
AI-based tomography is an important application and a new frontier of machine learning. AI, especially deep learning, has been widely used in computer vision and image analysis, which deal with existing images, improve them, and produce features. Since 2016, deep learning techniques are actively researched for tomography in the context of medicine. Tomographic reconstruction produces images of multi-dimensional structures from externally measured “encoded” data in the form of various transforms (integrals, harmonics, and so on). In this presentation, we provide a general background, highlight representative results, and discuss key issues that need to be addressed in this emerging field.

About:
AI-based X-ray Imaging System (AXIS) lab is led by Dr. Ge Wang, affiliated with the Department of Biomedical Engineering at Rensselaer Polytechnic Institute and the Center for Biotechnology and Interdisciplinary Studies in the Biomedical Imaging Center. AXIS lab focuses on innovation and translation of x-ray computed tomography, optical molecular tomography, multi-scale and multi-modality imaging, and AI/machine learning for image reconstruction and analysis, and has been continuously well funded by federal agencies and leading companies. AXIS group collaborates with Stanford, Harvard, Cornell, MSK, UTSW, Yale, GE, Hologic, and others, to develop theories, methods, software, systems, applications, and workflows.

Jan
19
Tue
2021
Cancer Early Detection Seminar Series – Thomas Kislinger, Ph.D. @ Zoom - See Description for Zoom Link
Jan 19 @ 11:00 am – 12:00 pm
Cancer Early Detection Seminar Series - Thomas Kislinger, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: Systematic identification of fluid-based biomarkers for ovarian and prostate cancer

 

Thomas Kislinger, Ph.D.
Professor & Chair
Department of Medical Biophysics
University of Toronto

Senior Scientist
Princess Margaret Cancer Centre

 

Zoom Webinar Details 
Meeting URL: https://stanford.zoom.us/s/94878578384
Dial: +1 650 724 9799 or +1 833 302 1536
Webinar ID: 948 7857 8384
Passcode: 692692
Register Here

 

ABOUT

Thomas Kislinger received his MSc in Analytical Chemistry from the University of Munich, Germany (1998). He completed his PhD in 2001, investigating the role of Advanced Glycation Endproducts in diabetic vascular complications at the University of Erlangen, Germany and Columbia University, New York. Between 2002 and 2006 he completed a post-doctoral fellowship at the University of Toronto. In 2006 he joined the Princess Margaret Cancer Centre as an independent investigator. Dr. Kislinger holds positions as Senior Scientist at the Princess Margaret Cancer Centre and as Professor and Chair at the University of Toronto in the Department of Medical Biophysics. The Kislinger lab applies proteomics technologies to translational and basic cancer biology. This includes the development of novel proteomics methodologies, identification of liquid biopsy signatures and the molecular identification of novel cell surface markers.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Mar
2
Tue
2021
Cancer Early Detection Seminar Series – Melissa Wong, Ph.D. @ Zoom - See Description for Zoom Link
Mar 2 @ 11:00 am – 12:00 pm
Cancer Early Detection Seminar Series - Melissa Wong, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: Disseminated cell hybrids as biomarkers for cancer detection, prognosis and treatment response

Melissa Wong, Ph.D.
Associate Professor and Vice Chair
Department of Cell, Development and Cancer Biology
Program Co-Lead, Knight Cancer Institute
Oregon Health & Science University

 

Zoom Details
Meeting URL: https://stanford.zoom.us/s/98184098662
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 981 8409 8662
Passcode: 084321

RSVP Here!

 

ABSTRACT

Metastatic progression defines the final stages of tumor evolution and underlies the majority of cancer-related deaths. The heterogeneity in disseminated tumor cell populations capable of seeding and growing in distant organ sites contributes to the development of treatment resistant disease.  We recently reported the identification of a novel tumor-derived cell population, circulating hybrid cells (CHCs), harboring attributes from both macrophages and neoplastic cells, including functional characteristics important to metastatic spread. These disseminated hybrids outnumber conventionally defined circulating tumor cells (CTCs) in cancer patients. It is unknown if CHCs represent a generalized cancer mechanism for cell dissemination, or if this population is relevant to the metastatic cascade. We detect CHCs in the peripheral blood of patients with cancer in myriad disease sites encompassing epithelial and non-epithelial malignancies. Further, we demonstrate that in vivo-derived hybrid cells harbor tumor-initiating capacity in murine cancer models and that CHCs from human breast cancer patients express stem cell antigens, features consistent with the ability to seed and grow at metastatic sites. We reveal heterogeneity of CHC phenotypes reflect key tumor features, including oncogenic mutations and functional protein expression. Importantly, this novel population of disseminated neoplastic cells opens a new area in cancer biology and renewed opportunity for battling metastatic disease.

 

ABOUT

The research focus of the Wong laboratory revolves around understanding the regulatory mechanisms that control epithelial stem cell homeostasis and their expansion in developmental, homeostasis and disease contexts, including cancer. I have substantial training and experience in intestinal stem cell investigation leveraging in vivo and ex vivo modeling, as well as in myriad cutting edge technologies (i.e. cyCIF, scRNA-seq). My publication record spans my post-doctoral fellowship in Dr. Jeffrey Gordon’s laboratory at Washington University School of Medicine, to studies in my own laboratory at Oregon Health & Science University. Our research impacts the understanding of regulatory mechanisms that govern cell state in the context of the evolving tissue microenvironment and changing cell signaling landscape, in development and disease.

 

Our studies in stem cell regulation led to the intriguing finding that stem cells can fuse with tissue macrophages in the context of injury repair and may impact tissue regeneration. We have extended these findings to the cancer setting, where cancer-macrophage fusions are detectible in primary and metastatic tumors, and my group recently identified and characterized these cells as a novel circulating tumor cell population. Importantly, our studies in cell culture, in mice and humans provide an indepth evaluation of hybrid cells to set the foundation for continued investigations into their biology, impact on disease progression or tissue regeneration, and use as a biomarker for disease burden. Importantly, we coined the term, circulating hybrid cell (CHC) for this novel population and reported they exist at higher levels than conventionally defined circulating tumor cells in the peripheral blood of cancer patients. This work was published in 2018 and highlighted by Science Magazine as one of the top ten publications in the cancer field in the science family journals. The science proposed in this U01 application leverage hybrid cell biology to assess treatment response and resistance in breast cancer patients undergoing targeted therapy. Our proposal leverages active collaborations with Dr. Young Hwan Young’s group to synergize biology with computation, as well as a number of other valuable collaborators to ensure success of the proposed, cutting-edge science.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Apr
30
Fri
2021
Racial Equity Challenge: Race in society @ Zoom
Apr 30 @ 12:00 pm – 1:00 pm
Racial Equity Challenge: Race in society @ Zoom

Targeted violence continues against Black Americans, Asian Americans, and all people of color. The department of radiology diversity committee is running a racial equity challenge to raise awareness of systemic racism, implicit bias and related issues. Participants will be provided a list of resources on these topics such as articles, podcasts, videos, etc., from which they can choose, with the “challenge” of engaging with one to three media sources prior to our session (some videos are as short as a few minutes). Participants will meet in small-group breakout sessions to discuss what they’ve learned and share ideas.

Please reach out to Marta Flory, flory@stanford.edu with questions. For details about the session, including recommended resources and the Zoom link, please reach out to Meke Faaoso at mfaaoso@stanford.edu.

May
11
Tue
2021
Cancer Early Detection Seminar Series – Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link
May 11 @ 11:00 am – 12:00 pm
Cancer Early Detection Seminar Series - Michael Berger, Ph.D. @ Zoom - See Description for Zoom Link

CEDSS: “Building a Scalable Clinical Genomics Program: How tumor, normal, and plasma DNA sequencing are informing cancer care, cancer risk, and cancer detection”

 

Michael Berger, Ph.D.

Elizabeth and Felix Rohatyn Chair & Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center

 

Zoom Details
Meeting URL: https://stanford.zoom.us/s/92559505314
Dial: US: +1 650 724 9799  or +1 833 302 1536 (Toll Free)
Meeting ID: 925 5950 5314
Passcode: 418727

11:00am – 12:00pm Seminar & Discussion
RSVP Here

 

ABSTRACT
Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of oncogenomic mutations that can be targeted therapeutically. To accelerate enrollment to clinical trials of molecularly targeted agents and guide treatment selection, we have established a center-wide, prospective clinical sequencing program at Memorial Sloan Kettering Cancer Center using a custom, paired tumor-blood normal sequencing assay (MSK-IMPACT), which we have used to profile more than 50,000 patients with solid tumors. Yet beyond just the characterization of tumor-specific alterations, the inclusion of blood DNA has readily enabled the identification of germline risk alleles and somatic mutations associated with clonal hematopoiesis. To complement this approach, we have also implemented a ‘liquid biopsy’ cfDNA panel (MSK-ACCESS) for cancer detection, surveillance, and treatment selection and monitoring. In my talk, I will describe the prevalence of somatic and germline genomic alterations in a real-world population, the clinical benefits of cfDNA assessment, and how clonal hematopoiesis can inform cancer risk and confound liquid biopsy approaches to cancer detection.

 

ABOUT
Michael Berger, PhD, holds the Elizabeth and Felix Rohatyn Chair and is Associate Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center, a multidisciplinary initiative to promote precision oncology through genomic analysis to guide the diagnosis and treatment of cancer patients. He is also an Associate Attending Geneticist in the Department of Pathology with expertise in cancer genomics, computational biology, and high-throughput DNA sequencing technology. His laboratory is developing experimental and computational methods to characterize the genetic makeup of individual cancers and identify genomic biomarkers of drug response and resistance. As Scientific Director of Clinical NGS in the Molecular Diagnostics Service, he oversees the development and bioinformatics associated with clinical sequencing assays, and he helped lead the development and implementation of MSK-IMPACT, a comprehensive FDA-authorized tumor sequencing panel that been used to profile more than 60,000 tumors from advanced cancer patients at MSK. The resulting data have enabled the characterization of somatic and germline biomarkers across many cancer types and the identification of mutations associated with clonal hematopoiesis. Dr. Berger also led the development of a clinically validated plasma cell-free DNA assay, MSK-ACCESS, which his laboratory is using to explore tumor evolution, acquired drug resistance, and occult metastatic disease. He received his Bachelor’s Degree in Physics from Princeton University and his Ph.D. in Biophysics from Harvard University.

 

Hosted by: Utkan Demirci, Ph.D.
Spon
sored by: The Canary Center & the Department of Radiology 
Stanford University – School of Medicine

Jul
16
Fri
2021
Radiology-Wide Research Conference @ Zoom – Details can be found here: https://radresearch.stanford.edu
Jul 16 @ 12:00 pm – 1:00 pm
Radiology-Wide Research Conference @ Zoom – Details can be found here: https://radresearch.stanford.edu

Radiology Department-Wide Research Meeting

• Research Announcements
• Mirabela Rusu, PhD – Learning MRI Signatures of Aggressive Prostate Cancer: Bridging the Gap between Digital Pathologists and Digital Radiologists
• Akshay Chaudhari, PhD – Data-Efficient Machine Learning for Medical Imaging

Location: Zoom – Details can be found here: https://radresearch.stanford.edu
Meetings will be the 3rd Friday of each month.

 

Hosted by: Kawin Setsompop, PhD
Sponsored by: the the Department of Radiology

Oct
6
Wed
2021
Early Detection of Cancer Conference @ Virtual Event
Oct 6 – Oct 8 all-day
Early Detection of Cancer Conference @ Virtual Event

Cancer Research UK, OHSU Knight Cancer Institute and the Canary Center at Stanford, present the Early Detection of Cancer Conference series. The annual Conference brings together experts in early detection from multiple disciplines to share ground breaking research and progress in the field.

The Conference is part of a long-term commitment to invest in early detection research, to understand the biology behind early stage cancers, find new detection and screening methods, and enhance uptake and accuracy of screening.

The 2021 conference will take place October 6-8 virtuallyFor more information visit the website: http://earlydetectionresearch.com/